The Future of Regulatory CMC Isn’t Another Consultant. It’s a Digital One.

by Edward Narke – Contact us now for our Case Study: Appointing a Virtual CMC Consultant

Most AI tools focus on writing regulatory documents. The next evolution is far more powerful. Imagine a digital Regulatory CMC consultant that can assess development strategies, identify submission risks, perform gap analyses, simulate FDA reviews, and generate high-quality regulatory content. In this article, we explore how AI is transforming Regulatory CMC from a document-writing exercise into an intelligent decision-support platform that helps sponsors move faster, reduce risk, and improve submission quality.

What happens when an FDA reviewer, CMC strategist, technical writer, and due diligence expert become one AI system?

For years, the pharmaceutical industry has relied on a familiar model.

Need a CMC strategy? Hire consultants.

Need Module 3 written? Hire more consultants.

Need a gap assessment before an FDA meeting? Bring in another expert.

The challenge is that expertise is expensive, difficult to scale, and often unavailable when sponsors need it most.

Today, Artificial Intelligence is changing that equation.

But not in the way most people think.

The future is not an AI that simply writes regulatory documents.

The future is an AI that thinks like a Regulatory CMC consultant.

Writing Is Not the Problem

Many organizations are currently focused on using AI to generate content.

That is useful.

However, authoring a Module 3 is only a small part of the overall challenge.

Before a single sentence is written, experienced CMC professionals are asking questions such as:

• Is the development program phase-appropriate?
• What information is missing?
• Are the specifications justified?
• Is the control strategy defensible?
• Does the stability package support the proposed shelf life?
• Are the analytical methods adequately qualified or validated?
• What questions will FDA ask during review?

These decisions represent the true value of Regulatory CMC expertise.

The document itself is simply the output.

Building a Digital CMC Consultant

At Enkrisi, we believe the next generation of AI platforms will operate much differently than today’s authoring tools.

Instead of:

Source Documents → AI Writer → Submission

The future looks more like:

Source Documents → Data Extraction → Regulatory Strategy → Gap Assessment → Authoring → FDA Review Simulation → Submission

This mirrors how experienced Regulatory CMC professionals actually work.

The AI becomes a virtual consultant that evaluates information, identifies risks, recommends actions, and then generates documentation aligned with the strategy.

Five Agents Every Regulatory Organization Will Need

Imagine a platform consisting of specialized AI agents working together.

Agent 1: The CMC Strategist

This agent evaluates development plans, regulatory pathways, and submission readiness.

It identifies risks before they become deficiencies and recommends the most efficient path forward.

Agent 2: The Development Advisor

This agent reviews:

• Formulation development
• Process development
• Analytical development
• Stability programs

It continuously identifies gaps and recommends next steps.

Agent 3: The Author

Once strategy is established, the authoring agent generates:

• IND Quality Modules
• NDA Module 3
• BLA Module 3
• Annual Reports
• Responses to Agency Questions

The writing becomes a reflection of the strategy rather than an isolated activity.

Agent 4: The FDA Reviewer

This may become the most valuable agent of all.

Before submission, the platform reviews the application through the lens of an FDA reviewer.

Potential deficiencies, inconsistencies, and missing information are identified before they reach the Agency.

Agent 5: The Due Diligence Specialist

For investors, licensing teams, and acquirers, the platform evaluates technical, regulatory, and CMC risks across development programs.

What once required weeks of expert review can be performed in hours.

Why This Matters

The pharmaceutical industry is under increasing pressure to move faster while controlling costs.

Traditional consulting models struggle to scale.

AI offers an opportunity to democratize access to high-level Regulatory CMC expertise.

Small biotech companies that previously could not afford senior consultants may soon have access to a digital Regulatory CMC advisor available 24 hours a day.

That does not eliminate the need for human experts.

It amplifies them.

The most successful organizations will combine experienced regulatory professionals with AI systems capable of processing thousands of pages of source documentation in minutes.

The Enkrisi Vision

At Enkrisi, we do not see AI as a replacement for Regulatory CMC professionals.

We see it as an extension of them.

The goal is not to build another writing tool.

The goal is to create a digital Regulatory CMC consultant capable of helping sponsors think, plan, assess risk, and execute more effectively than ever before.

The future of Regulatory CMC will belong to organizations that combine human expertise with intelligent systems.

The technology is already here.

The question is no longer whether AI will transform Regulatory CMC.

The question is who will embrace it first.